Author
Listed:
- Jorge-Eduardo Martínez-Pérez
(University of Murcia)
- Fernando-Ignacio Sánchez-Martínez
(University of Murcia)
- José-María Abellán-Perpiñán
(University of Murcia)
- Domingo Pascual-Figal
(University of Murcia)
Abstract
Aim This study aims to estimate the value of a statistical life (VSL) in the context of atherosclerotic cardiovascular disease (ASCVD) in Spain using a contingent valuation/standard gamble (CV/SG) chained approach. Methods The study employed a two-stage preference elicitation method that combined contingent valuation and a modified standard gamble technique. Specifically, willingness-to-pay and willingness-to-accept values were obtained for two health states depicting hypothetical outcomes following cardiovascular events. Subsequently, relative utility losses for the health states were derived using a modified standard gamble framing two risky choices. Chaining these elicited values allowed for VSL calculation without requiring direct valuation of small mortality risk reductions. The study was conducted through in-person interviews with a representative sample of 412 Spanish adults selected by stratified quotas. Results The estimated VSL range is from 1.59 to 2.06 million euros. Minor differences emerge between VSL figures on the basis of each of the two health states. These VSL estimates for ASCVD are congruent with the recent update of the official VSL estimated for Spain in the context of road traffic accidents, though the upper limit of the range is slightly higher (almost 9%). Conclusions VSL estimates align with existing ranges in other European countries, particularly in the context of road safety, where a significant portion of existing studies is concentrated. Comparisons with other contexts, involving cardiovascular diseases, also lend support to the estimates presented here.
Suggested Citation
Jorge-Eduardo Martínez-Pérez & Fernando-Ignacio Sánchez-Martínez & José-María Abellán-Perpiñán & Domingo Pascual-Figal, 2025.
"The Monetary Value of a Statistical Life in the Context of Atherosclerotic Cardiovascular Disease,"
PharmacoEconomics, Springer, vol. 43(6), pages 677-689, June.
Handle:
RePEc:spr:pharme:v:43:y:2025:i:6:d:10.1007_s40273-025-01482-3
DOI: 10.1007/s40273-025-01482-3
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:43:y:2025:i:6:d:10.1007_s40273-025-01482-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.